SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Greenlee RT,Murray T,Bolden S, et al. Cancer statistics, 2000. CA Cancer J Clin. 2000; 50: 733.
  • 2
    Ozols R,Schwartz P,Eifel P. Ovarian cancer, fallopian tube carcinoma and peritoneal carcinoma. In: DeVitaVT,HellmanS,RosenbergSA, eds. Cancer: Principles and Practice of Oncology. Philadelphia, Pa: Lippincott-Raven; 1997: 15021539.
  • 3
    Gordon AN,Fleagle JT,Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001; 19: 33123322.
  • 4
    Bookman MA,Darcy KM,Clarke-Pearson D, et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol. 2003; 21: 283290.
  • 5
    Hart CE,Forstrom JW,Kelly JD, et al. Two classes of PDGF receptor recognize different isoforms of PDGF. Science. 1988; 240: 15291531.
  • 6
    Eriksson A,Siegbahn A,Westermark B, et al. PDGF alpha- and beta-receptors activate unique and common signal transduction pathways. EMBO J. 1992; 11: 543550.
  • 7
    Yao R,Cooper GM. Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science. 1995; 267: 20032006.
  • 8
    Huang JS,Huang SS,Deuel TF. Transforming protein of simian sarcoma virus stimulates autocrine growth of SSV-transformed cells through PDGF cell-surface receptors. Cell. 1984; 39: 7987.
  • 9
    Greenhalgh DG,Sprugel KH,Murray MJ, et al. PDGF and FGF stimulate wound healing in the genetically diabetic mouse. Am J Pathol. 1990; 136: 12351246.
  • 10
    Heldin CH,Ostman A,Ronnstrand L. Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta. 1998; 1378: F79F113.
  • 11
    Yu J,Moon A,Kim HR. Both platelet-derived growth factor receptor (PDGFR)-alpha and PDGFR-beta promote murine fibroblast cell migration. Biochem Biophys Res Commun. 2001; 282: 697700.
  • 12
    Cao R,Brakenhielm E,Li X, et al. Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-alphaalpha and -alphabeta receptors. FASEB J. 2002; 16: 15751583.
  • 13
    Bergers G,Song S,Meyer-Morse N, et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003; 111: 12871295.
  • 14
    Pietras K,Rubin K,Sjoblom T, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 2002; 62: 54765484.
  • 15
    Baranowska-Kortylewicz J,Abe M,Pietras K, et al. Effect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy. Cancer Res. 2005; 65: 78247831.
  • 16
    Matei D,Graeber TG,Baldwin RL, et al. Gene expression in epithelial ovarian carcinoma. Oncogene. 2002; 21: 62896298.
  • 17
    Henriksen R,Funa K,Wilander E, et al. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res. 1993; 53: 45504554.
  • 18
    Schmandt RE,Broaddus R,Lu KH, et al. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer. 2003; 98: 758764.
  • 19
    Matei D,Chang DD,Jeng MH. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation. Clin Cancer Res. 2004; 10: 681690.
  • 20
    Lassus H,Sihto H,Leminen A, et al. Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma. Br J Cancer. 2004; 91: 20482055.
  • 21
    Spentzos D,Levine DA,Ramoni MF, et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol. 2004; 22: 47004710.
  • 22
    Sihto H,Sarlomo-Rikala M,Tynninen O, et al. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J Clin Oncol. 2005; 23: 4957.
  • 23
    Matei D,Emerson RE,Lai YC, et al. Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer. Oncogene. 2006; 25: 20602069.
  • 24
    Buchdunger E,Zimmermann J,Mett H, et al. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci USA. 1995; 92: 25582562.
  • 25
    Druker BJ,Sawyers CL,Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001; 344: 10381042.
  • 26
    Demetri GD,von Mehren M,Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347: 472480.
  • 27
    Matei D,Kelich S,Cao L, et al. PDGF BB induces VEGF secretion in ovarian cancer. Cancer Biol Ther. 2007: 6: 19511959.
  • 28
    Alberts DS,Liu PY,Wilczynski SP, et al. Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211). Int J Gynecol Cancer. 2007; 17: 784788.
  • 29
    Coleman RL,Broaddus RR,Bodurka DC, et al. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol. 2006; 101: 126131.
  • 30
    Posadas EM,Kwitkowski V,Kotz HL, et al. A prospective analysis of imatinib-induced c-kit modulation in ovarian cancer: a phase II clinical study with proteomic profiling. Cancer. 2007; 110: 309317.
  • 31
    Pietras K,Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose “chemo-switch” regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol. 2005; 23: 939952.
  • 32
    Vlahovic G,Ponce AM,Rabbani Z, et al. Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. Br J Cancer. 2007; 97: 735740.
  • 33
    Mathew P,Fidler IJ,Logothetis CJ. Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer. Semin Oncol. 2004; 31: 2429.
  • 34
    Cheng JQ,Godwin AK,Bellacosa A, et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA. 1992; 89: 92679271.
  • 35
    Cheng JQ,Jiang X,Fraser M, et al. Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway. Drug Resist Updat. 2002; 5: 131146.
  • 36
    Mathew P,Thall PF,Jones D, et al. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol. 2004; 22: 33233329.
  • 37
    Therasse P,Arbuck SG,Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205216.
  • 38
    Rustin GJ. Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol. 2003; 21: 187193.
  • 39
    Le Page C,Koumakpayi IH,Alam-Fahmy M, et al. Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patients. Br J Cancer. 2006; 94: 19061912.
  • 40
    Kavanagh JJ,Kudelka AP,de Leon CG, et al. Phase II studyof docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res. 1996; 2: 837842.
  • 41
    Jayson GC,Parker GJ,Mullamitha S, et al. Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab′, leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol. 2005; 23: 973981.
  • 42
    Tonary AM,Macdonald EA,Faught W, et al. Lack of expression of c-KIT in ovarian cancers is associated with poor prognosis. Int J Cancer. 2000; 89: 242250.
  • 43
    Wilczynski SP,Chen YY,Chen W, et al. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers. Hum Pathol. 2005; 36: 242249.
  • 44
    Rose PG,Blessing JA,Ball HG, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003; 88: 130135.
  • 45
    Markman M,Zanotti K,Webster K, et al. Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum. Gynecol Oncol. 2003; 91: 573576.
  • 46
    Verschraegen CF,Sittisomwong T,Kudelka AP, et al. Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. J Clin Oncol. 2000; 18: 27332739.
  • 47
    Terauchi F,Hirano T,Taoka H, et al. Weekly docetaxel forpatients with platinum/paclitaxel/irinotecan-resistant relapsed ovarian cancer: a phase I study. Int J Clin Oncol. 2003; 8: 348351.
  • 48
    Tinker AV,Gebski V,Fitzharris B, et al. Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel—ANZGOG 02-01. Gynecol Oncol. 2007; 104: 647653.
  • 49
    Petrylak DP,Tangen CM,Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2007; 351: 15131520.
  • 50
    Fennelly D,Aghajanian C,Shapiro F, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol. 1997; 15: 187192.
  • 51
    Markman M,Hall J,Spitz D, et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol. 2002; 20: 23652369.
  • 52
    Helft PR,Daugherty CK. Are we taking without giving in return? The ethics of research-related biopsies and the benefits of clinical trial participation. J Clin Oncol. 2006; 24: 47934795.